Advertisement

Epidemiological Data and Treatment of Gastroenteropancreatic Neuroendocrine Neoplasms: Insights From Tertiary Referral Hospitals in Latvia

  • Margarita PtasnukaEmail author
  • Arturs Ozolins
  • Zenons Narbuts
  • Arturs Truskovs
  • Maris Sperga
  • Haralds Plaudis
Original Scientific Report
  • 15 Downloads

Abstract

Background

Gastroenteropancreatic neuroendocrine neoplasms (GEP-NEN) are rare, heterogeneous group which tend to rise in incidence. Epidemiological profile and outcomes of GEP-NEN may vary among countries. The aim of study was to provide baseline clinical and histopathological features of patients with GEP-NEN from tertiary referral hospitals in Latvia.

Methods

A retrospective study of patients with histologically confirmed diagnosis of GEP-NEN treated between 2006 and 2018. Joinpoint regression modeling was used to estimate annual percentage change (APC) for incidence trends. Overall survival (OS) rate was obtained by Kaplan–Meier method.

Results

In total, 205 patients were included. The median age at diagnosis was 61.0 (IQR 52.0–70.5) years, 69.3% were females. The age-adjusted incidence per 100 000 inhabitants increased from 0.03 in 2006 to 0.67 in 2018 with APC of 24.1%, p < 0.005. The most common primary tumor site was pancreas (30.7%), followed by stomach (24.9%) and small intestine (20.5%). Non-functional tumors are present in 83.4%, while carcinoid syndrome in 7.8%. Stage IV metastatic disease was present in 27.8% tumors. The majority of patients (82%) received an operation with radical or palliative intent. The 1- and 3-year OS rate were 88.0% (95% CI 83.3–92.7) and 77.1% (95% CI 70.4–83.8), respectively. Increasing tumor grade, stage and the presence of distant metastases were associated with significantly worse OS.

Conclusion

Our study highlights increasing incidence of GEP-NEN in Latvia. The most common primary site was pancreas and surgery considered as main modality of treatment. Registry and long-term data collection are necessary to develop GEP-NEN management concept in Latvia.

Notes

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

References

  1. 1.
    Massironi S, Conte D, Rossi R et al (2015) Somatostatin analogues in functioning gastroenteropancreatic neuroendocrine tumours: literature review, clinical recommendations and schedules. Scand J Gastroenterol 51(5):513–523CrossRefGoogle Scholar
  2. 2.
    Dasari A, Shen C, Halperin D et al (2017) Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine Tumors in the United States. JAMA Oncol 3(10):1335–1342CrossRefGoogle Scholar
  3. 3.
    Tian F, Cai Y, Zhuang L et al (2018) Clinicopathological features and prognosis of patients with gastric neuroendocrine tumors: a population-based study. Cancer Med 7:5359–5369CrossRefGoogle Scholar
  4. 4.
    Garcia-Carbonero R, Capdevila J, Crespo-Herrero G et al (2010) Incidence, patterns of care and prognostic factors for outcome of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): results from the National Cancer Registry of Spain (RGETNE). Ann Oncol 21:1794–1803CrossRefGoogle Scholar
  5. 5.
    Pape -FU, Berndt U, Muller-Nordhorn J et al (2008) Prognostic factors of long-term outcome in gastroenteropancreatic neuroendocrine tumours. Endocr Relat Cancer 15:1083–1097CrossRefGoogle Scholar
  6. 6.
    Fraenkel M, Kim MK, Faggiano A et al (2012) Epidemiology of gastroenteropancreatic neuroendocrine tumours. Best Pract Res Clin Gastroenterol 26:691–703CrossRefGoogle Scholar
  7. 7.
    EU council (2009) Council Recommendation of 8 June 2009 on an action in the field of rare diseases. Official Journal of the European Union 151:710Google Scholar
  8. 8.
    Ahmad OB, Boschi-Pinto C, Lopez AD et al (2001) Age Standardization of Rates: A new WHO Standard. World Health Organization, GenevaGoogle Scholar
  9. 9.
    Zhong Q, Chen Q, Xie J et al (2018) Incidence trend and conditional survival estimates of gastroenteropancreatic neuroendocrine tumors: a large population-based study. Cancer Med 7:3521–3533CrossRefGoogle Scholar
  10. 10.
    Hallet J, Law C, Cukier M et al (2015) Exploring the rising incidence of neuroendocrine tumors: A population-based analysis of epidemiology, metastatic presentation, and outcomes. Cancer 121:589–597CrossRefGoogle Scholar
  11. 11.
    Ito T, Sasano H, Tanaka M et al (2010) Epidemiological study of gastroenteropancreatic neuroendocrine tumors in Japan. J Gastroenterol 45:234–243CrossRefGoogle Scholar
  12. 12.
    Trofimiuk-Müldner M, Lewkowicz E, Wysocka K et al (2017) Epidemiology of gastroenteropancreatic neuroendocrine neoplasms in Krakow and Krakow district in 2007–2011. Endokrynologia Polska 68(1):42–46CrossRefGoogle Scholar
  13. 13.
    Scherubl H, Streller B, Stabenow R et al (2013) Clinically detected gastroenteropancreatic neuroendocrine tumors are on the rise: epidemiological changes in Germany. World J Gastroenterol 19(27):9012–9019CrossRefGoogle Scholar
  14. 14.
    Cetinkaya R, Aagnes B, Thiis-Evensen E et al (2017) Trends in incidence of neuroendocrine neoplasms in norway: a report of 16,075 cases from 1993 through 2010. Neuroendocrinology 104:1–10CrossRefGoogle Scholar
  15. 15.
    Sandvik OM, Søreide K, Gudlaugsson E et al (2016) Epidemiology and classification of gastroenteropancreatic neuroendocrine neoplasms using current coding criteria. Br J Surg 103(3):226–232CrossRefGoogle Scholar
  16. 16.
    Pinto MP, Medel M, Carrillo D et al (2019) Chilean registry for neuroendocrine tumors: a latin American perspective. Horm Cancer 10:3–10CrossRefGoogle Scholar
  17. 17.
    O’Conner J, Marmissolle F, Bestani C et al (2014) Observational study of patients with gastroenteropancreatic and bronchial neuroendocrine tumors in Argentina: results from the large database of a multidisciplinary group clinical multicenter study. Mol Clin Oncol 2:673–684CrossRefGoogle Scholar
  18. 18.
    Lombard-Bohas C, Mitry E, O’Toole D et al (2009) Thirteen-month registration of patients with gastroenteropancreatic endocrine tumours in France. Neuroendocrinology 89:217–222CrossRefGoogle Scholar
  19. 19.
    Gudmundsdottir H, Möller PH, Jonasson JG et al (2019) Gastroenteropancreatic neuroendocrine tumors in Iceland: a population-based study. Scand J Gastroenterol 54(1):69–75CrossRefGoogle Scholar
  20. 20.
    Niederle MB, Niederle B (2011) Diagnosis and treatment of gastroenteropancreatic neuroendocrine tumors: current data on a prospectively collected, retrospectively analyzed clinical multicenter investigation. Oncologist 16:602–613CrossRefGoogle Scholar
  21. 21.
    Zhang M, Zhao P, Shi X et al (2017) Clinicopathological features and prognosis of gastroenteropancreatic neuroendocrine neoplasms in a Chinese population: a large, retrospective single-centre study. BMC Endocr Disord 17:39CrossRefGoogle Scholar
  22. 22.
    Halperin DM, Shen C, Dasari A et al (2017) Frequency of carcinoid syndrome at neuroendocrine tumour diagnosis: a population-based study. The Lancet Oncology 18:525–534CrossRefGoogle Scholar
  23. 23.
    Nikou GC, Pazaitou-Panayiotou K, Dimitroulopoulos D et al (2016) Results of a prospective multicenter neuroendocrine tumor registry reporting on clinicopathologic characteristics of Greek patients. BMC Endocr Disord 16:8CrossRefGoogle Scholar
  24. 24.
    Garcia-Carbonero R, Capdevila J, Crespo-Herrero G et al (2010) Incidence, patterns of care and prognostic factors for outcome of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): results from the National Cancer Registry of Spain (RGETNE). Ann Oncol 21:1794–1803CrossRefGoogle Scholar
  25. 25.
    Sundin A (2012) Radiological and nuclear medicine imaging of gastroenteropancreatic neuroendocrine tumours. Best Pract Res Clin Gastroenterol 26:803–818CrossRefGoogle Scholar
  26. 26.
    Yuan C, Wang J, Xiu D et al (2016) Meta-analysis of Liver Resection Versus Nonsurgical Treatments for Pancreatic Neuroendocrine Tumors with Liver Metastases. Annals of Surgical Oncology 23:244–249CrossRefGoogle Scholar
  27. 27.
    Lewis A, Raoof M, Ituarte PH, et al (2018) Resection of the Primary Gastrointestinal Neuroendocrine Tumor Improves Survival with or without Liver Treatment. Ann Surg.  https://doi.org/10.1097/SLA.0000000000002809 CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Wang Y, Lin Y, Xue L et al (2012) Relationship between clinical characteristics and survival of gastroenteropancreatic neuroendocrine neoplasms: a single-institution analysis (1995–2012) in South China. Bmc Endocr Disord 12:30CrossRefGoogle Scholar
  29. 29.
    Lewkowicz E, Muldner-Trofimiuk M, Wysocka K et al (2015) Gastroenteropancreatic neuroendocrine neoplasms: a 10-year experience of a single center. Pol Arch Med Wewn 125(5):337–346PubMedGoogle Scholar

Copyright information

© Société Internationale de Chirurgie 2019

Authors and Affiliations

  • Margarita Ptasnuka
    • 1
    • 2
    Email author
  • Arturs Ozolins
    • 1
    • 3
  • Zenons Narbuts
    • 1
    • 3
  • Arturs Truskovs
    • 1
  • Maris Sperga
    • 4
  • Haralds Plaudis
    • 1
    • 2
  1. 1.Riga Stradins UniversityRigaLatvia
  2. 2.Department of General and Emergency SurgeryRiga East Clinical University HospitalRigaLatvia
  3. 3.Department of SurgeryPauls Stradins Clinical University HospitalRigaLatvia
  4. 4.Department of Infectious PathologyPathology CenterRigaLatvia

Personalised recommendations